Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine

Journal of Clinical Pharmacology

Volumn 39, Issue 2, 1999, Pages 192-199

  Goldberg, Michael R ^a   Lowry, Richard C ^a   Musson, Donald G ^a   Birk, Kimberly L ^a   Fisher, Allison ^a   DePuy, M Elizabeth ^a   Shadle, Craig R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; RIZATRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MIGRAINE; MOOD; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADULT; AFFECT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BLOOD PRESSURE; BODY TEMPERATURE; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEART RATE; HUMANS; MALE; PAROXETINE; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; STATISTICS, NONPARAMETRIC; TRIAZOLES; TRYPTAMINES;

EID: 0032949704     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007633     Document Type: Article

References (21)

1. 1D receptor agonist, MK-462. Cephalalgia 1995;15:203P.
2. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD for the Dutch/US Rizatriptan Study Group: Rizatriptan vs Sumatriptan in the Acute Treatment of Migraine. Arch Neurol Chicago 1996;53(11):1132-1137.
3. Kramer MS, Matzura-Wolfe D, Getson A, Polis A, Reines SA, and the Rizatriptan Multiple Attack Study Group: Placebo-controlled, double-blind study of rizatriptan in multiple attacks of acute migraine. Neurology 1997;43(Suppl. 2):A68-A69.
4. Block GA, Smith M, Jiang K, Reines S, Teall J, and the Rizatriptan 022 Study Group: Rizatriptan (MK-0462) for the acute treatment of migraine and migraine recurrence. Neurology 1997;48(3, Suppl. 2):A68.
5. Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M, Mant T: Initial human experience with MK-462 (rizatriptan): A novel 5-HT-1D agonist. Br J Clin Pharmacol 1997;43(1):49-54.
6. Cheng HC, Polvino WJ, Sciberras D, Yogendran L, Cerchio KA, Christie K, Olah TV, McLoughlin D, James I, Rogers JD: Pharmacokinetics and food interaction of MK-462 in healthy males. Biopharm Drug Dispos 1996;17:17-24.
7. Waalinder J, Feighner JP: Novel selective serotonin reuptake inhibitors, part I. J Clin Psychiatry 1992;53:107-112.
8. Dechant KL, Clissold SP: Paroxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:225-253.
9. Lund J, Lomholt B, Fabricius J, Christensen JA, Bechgaard E: The pharmacokinetics and the effect on blood 5-HT of paroxetine in man. Nordisk Psykiatrisk Tidsskrift 1979;33:450-454.
10. Bond A, Lader M: The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-218.
11. 1D, agonist MK-462 and sumatriptan in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatography 1996;726:115-124.
12. Barrish A, Olah TV, Gatto GJ, Michel KB, Dobrinska MR, Gilbert JD: The use of stable isotope labeling and liquid chromatography/tandem mass spectrometry techniques to study the pharmacokinetics and bioavailability of the antimigraine drug, MK-0462 (rizatriptan) in dogs. Rapid Com Mass Spec 1996;10:1033-1037.
13. Jones B, Kenward M: Design and Analysis of Crossover Trials. London: Chapman & Hall, 1989.
14. Hollander M: The one-sample location problem. In, Wiley J. & Sons, (eds.): Nonparametric Statistical Methods. New York: John Wiley, 1973;26-38.
15. Sindrup SH, Brøsen K, Gram LF: Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Phamacol Ther 1992;51:288-295.
16. Stewart WF, Lipton RB, Celentano DD, Reed ML: Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. JAMA 1992;267(1):64-69.
17. Blier P, Bergeron R: The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharm 1995;15:106-109.
18. Leung M: Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Headache 1995;35:488-489.
19. Sternback H: The serotonin syndrome. Am J Psychiatry 1991;148:705-713.
20. Sporer KA: The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Safety 13:94-104.
21. Tietjen GE: Migrain therapy and the serotonin syndrome (abstract). Cephalalgia 1995;15:114.